Company intelligence
NSF - Life Sciences
NSF provides world-class consulting, training, clinical, and auditing services to the life sciences industry
About NSF - Life Sciences
NSF works with pharmaceutical, medical devices, and in vitro diagnostic companies, large and small, to provide highly customized end-to-end services throughout the product lifecycle, from clinical trials to post-market surveillance. We are a global provider of clinical trials, training, consultancy, certification and auditing services to the life sciences industry. We have an outstanding international reputation in quality management and regulatory compliance. We provide comprehensive solutions for the life sciences industry from experts you can trust. Our team includes former FDA, EU and MHRA regulators as well as industry experts. We combine regulatory knowledge with industry best practices to provide our clients with tailored quality, compliance and regulatory services About NSF For 80 years our mission has remained the same: protect and improve human health. Our Values Building a healthy culture and looking after our people is fundamental to achieving our mission—and underpinning everything we do. Everything, not least client focus and growth, is built upon this. Our culture starts with four core values: Do the Right Thing; Treat People Well, Relentlessly Pursue Excellence, and We Are One NSF. These core values are the principles that guide all of NSF’s actions. Work at NSF - careers - https://www.nsf.org/about-nsf/careers
Verified activity
Signals from NSF - Life Sciences
12 published signals
People
NSF - Life Sciences QP training was developed for Dalia Geneidi of Ourvita to step back from day-to-day responsibilities and develop a more pragmatic approach to solving problems.
Reported by NSF - Life Sciences
Presence & Recognition
NSF - Life Sciences is the official training provider for SupplySide Global 2026, inviting dietary supplement industry professionals to join its GMP and regulatory compliance training program.
Reported by NSF - Life Sciences
Capital & Finance
NSF - Life Sciences reported that Medtronic bumped its FY27 guidance and the stock jumped that afternoon.
Reported by Joseph Brennan, MBA
Presence & Recognition
NSF - Life Sciences is attending SAWC Fall 2026 in Las Vegas to discuss innovative wound care, regenerative medicine, biologics, and medical device companies.
Reported by Richard Lebrun Trachy
Research & Knowledge
NSF - Life Sciences announced that ANVISA's 2026–2027 Regulatory Agenda includes a review of whether international manufacturers should participate in MDSAP to obtain Brazilian GMP certification.
Reported by NSF - Life Sciences
Research & Knowledge
NSF - Life Sciences published its latest newsletter covering regulatory updates, industry trends, expert insights, and upcoming events shaping the future of life sciences, pharmaceuticals, and medical devices.
Reported by NSF - Life Sciences
Presence & Recognition
NSF - Life Sciences announced that on 25 September, Marie O’Callaghan and Susanne Weps will discuss how a more integrated approach can help teams reduce submission risk for combination products.
Reported by NSF - Life Sciences
Presence & Recognition
NSF - Life Sciences is attending the PDA/FDA Joint Regulatory Conference in Washington, DC this September.
Reported by NSF - Life Sciences
Presence & Recognition
NSF - Life Sciences is attending SupplySide Global 2026 for expert-led GMP and regulatory compliance training for dietary supplement professionals.
Reported by NSF - Life Sciences
Legal & Regulatory
NSF - Life Sciences announced that the EMA published Annex 22, the first AI-specific annex in the EU GMP Guide, detailing what a validated AI system looks like under GMP.
Reported by Joseph Brennan, MBA
Presence & Recognition
NSF - Life Sciences is offering upcoming courses on pharmaceutical law and administration, GMP PQS Lead Auditor, pharmaceutical microbiology, and medicinal chemistry and therapeutics.
Reported by NSF - Life Sciences
Legal & Regulatory
NSF - Life Sciences confirmed that China beat the U.S. on drug launches, with the tally showing real data.
Reported by Joseph Brennan, MBA